BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 9929937)

  • 21. Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications.
    Klastersky J; Paesmans M; Georgala A; Muanza F; Plehiers B; Dubreucq L; Lalami Y; Aoun M; Barette M
    J Clin Oncol; 2006 Sep; 24(25):4129-34. PubMed ID: 16943529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Febrile neutropenia in cancer patients in a tertiary care medical center in Lebanon: microbial spectrum and outcome.
    Hamzeh F; Kanj SS; Uwaydah M
    J Med Liban; 2000; 48(3):136-42. PubMed ID: 11268566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cefepime monotherapy is as effective as ceftriaxone plus amikacin in pediatric patients with cancer and high-risk febrile neutropenia in a randomized comparison.
    Pereira CA; Petrilli AS; Carlesse FA; Luisi FA; da Silva KV; de Martino Lee ML
    J Microbiol Immunol Infect; 2009 Apr; 42(2):141-7. PubMed ID: 19597646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of guideline for treatment of febrile neutropenia in pediatric cancer at Siriraj Hospital.
    Sanpakit K; Phuakpet K; Veerakul G; Narkbunnam N; Chokephaibulkit K
    J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S124-34. PubMed ID: 16858853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outpatient treatment of fever and neutropenia for low risk pediatric cancer patients.
    Mullen CA; Petropoulos D; Roberts WM; Rytting M; Zipf T; Chan KW; Culbert SJ; Danielson M; Jeha SS; Kuttesch JF; Rolston KV
    Cancer; 1999 Jul; 86(1):126-34. PubMed ID: 10391572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Retrospective cost analysis of management of febrile neutropenia in cancer patients in Spain.
    Mayordomo JI; López A; Viñolas N; Castellanos J; Pernas S; Domingo Alonso J; Frau A; Layola M; Antonio Gasquet J; Sánchez J;
    Curr Med Res Opin; 2009 Oct; 25(10):2533-42. PubMed ID: 19722781
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Fever profile of febrile neutropenia in patients treated with cancer chemotherapy for hematological malignancies].
    Tamai Y; Imataki O; Kawakami K
    Gan To Kagaku Ryoho; 2010 May; 37(5):859-62. PubMed ID: 20495316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
    Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
    Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Febrile neutropenia in children with cancer: a retrospective Norwegian multicentre study of clinical and microbiological outcome.
    Stabell N; Nordal E; Stensvold E; Gammelsrud KW; Lund B; Taxt A; Buhring F; Greve-Isdahl M; Fornebo HP; Simonsen GS; Klingenberg C
    Scand J Infect Dis; 2008; 40(4):301-7. PubMed ID: 17918015
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
    Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
    Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cefepime or carbapenem treatment for febrile neutropenia as a single agent is as effective as a combination of 4th-generation cephalosporin + aminoglycosides: comparative study.
    Tamura K; Matsuoka H; Tsukada J; Masuda M; Ikeda S; Matsuishi E; Kawano F; Izumi Y; Uike N; Utsunomiya A; Saburi Y; Shibuya T; Imamura Y; Hanada S; Okamura S; Gondoh H;
    Am J Hematol; 2002 Dec; 71(4):248-55. PubMed ID: 12447952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience with cefepime versus meropenem as empiric monotherapy for neutropenia and fever in pediatric patients with solid tumors.
    Oguz A; Karadeniz C; Citak EC; Cil V; Eldes N
    Pediatr Hematol Oncol; 2006; 23(3):245-53. PubMed ID: 16517540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients.
    Glasmacher A; von Lilienfeld-Toal M; Schulte S; Hahn C; Schmidt-Wolf IG; Prentice A
    Clin Microbiol Infect; 2005 Oct; 11 Suppl 5():17-23. PubMed ID: 16138815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful introduction and audit of a step-down oral antibiotic strategy for low risk paediatric febrile neutropaenia in a UK, multicentre, shared care setting.
    Dommett R; Geary J; Freeman S; Hartley J; Sharland M; Davidson A; Tulloh R; Taj M; Stoneham S; Chisholm JC
    Eur J Cancer; 2009 Nov; 45(16):2843-9. PubMed ID: 19616427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients.
    Oude Nijhuis C; Kamps WA; Daenen SM; Gietema JA; van der Graaf WT; Groen HJ; Vellenga E; Ten Vergert EM; Vermeulen KM; de Vries-Hospers HG; de Bont ES
    J Clin Oncol; 2005 Oct; 23(30):7437-44. PubMed ID: 16234511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early hospital discharge with oral antimicrobial therapy in patients with hematologic malignancies and low-risk febrile neutropenia.
    Girmenia C; Russo E; Carmosino I; Breccia M; Dragoni F; Latagliata R; Mecarocci S; Morano SG; Stefanizzi C; Alimena G
    Ann Hematol; 2007 Apr; 86(4):263-70. PubMed ID: 17225113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin.
    Chamilos G; Bamias A; Efstathiou E; Zorzou PM; Kastritis E; Kostis E; Papadimitriou C; Dimopoulos MA
    Cancer; 2005 Jun; 103(12):2629-35. PubMed ID: 15856427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia.
    Choi CW; Sung HJ; Park KH; Yoon SY; Kim SJ; Oh SC; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
    Am J Hematol; 2003 Aug; 73(4):263-6. PubMed ID: 12879430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.